List view / Grid view

Sandoz

 

Sandoz proposed biosimilars recommended for EU approval

25 April 2017 | By Niamh Marriott, Junior Editor

The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.

EMA accepts MAA for Sandoz’s biosimilar etanercept

8 December 2015 | By Victoria White

Sandoz is seeking approval for all indications included in the label of the reference product which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...